X

Drug Profile

HTL 9936

Alternative Names: HTL-0009936; HTL-9936

Latest Information Update: 02 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Heptares Therapeutics
Developer Nxera Pharma
Class Antidementias; Nootropics; Small molecules
Mechanism of Action Muscarinic M1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Alzheimer's disease
No development reported Cognition disorders

Most Recent Events

31 Mar 2024 Sosei Heptares is now called Nxera Pharma
24 Nov 2021 Preclinical trials in Alzheimer's disease in United Kingdom (PO)
22 Nov 2021 HTL 9936 licensed to Neurocrine Biosciences worldwide except Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com